NeuroPharmac 2020

Volume 5 (Issue 1, 2, 3) 2020 Current off-label Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19) https://doi.org/10.37881/1.511 2020, Volume 5, Issue 1 (January-April) [Download Full PDF] Urgent health challenges for the next decade 2030: World Health Organization https://doi.org/10.37881/1.512 2020, Volume 5, Issue 1 (January-April) [Download Full PDF] Lamotrigine and Phenytoin indicated for epilepsy recalled by the manufacturer in America https://doi.org/10.37881/1.513 2020, Volume 5, Issue 1 (January-April) [Download Full PDF] Traditional Approaches and Medicinal Plants in Treatment of Epilepsy in West and East Africa https://doi.org/10.37881/1.521 2020, Volume 5, Issue…

NeuroPharmac 2019

Volume 4 (Issue 1, 2, 3) 2019 Autism Spectrum Disorder: Medications overview https://doi.org/10.37881/1.411 2019, Volume 4, Issue 1 (January-April) [Download Full PDF] FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome https://doi.org/10.37881/1.412 2019, Volume 4, Issue 1 (January-April) [Download Full PDF] Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review https://doi.org/10.37881/1.413 2019, Volume 4, Issue 1 (January-April) [Download Full PDF] Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura https://doi.org/10.37881/1.414 2019, Volume 4,…